Value of p16INK4a in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology

Cancer Cytopathology

Volumn 120, Issue 4, 2012, Pages 276-282

  Alameda, Francesc ^a,b   Juanpere, Nuria ^a   Pijuan, Lara ^a   Lloveras, Belen ^a   Gimeno, Javier ^a   Baró, Teresa ^a   Salido, Marta ^a   Serrano, Sergio ^a,b   Lloreta, Josep ^a,c  

^a Department of Pathology   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

P16INK4a; Urinary bladder; Urinary cytology; Urothelial carcinoma; Voided urine

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 20; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY; BLADDER TUMOR; CANCER GRADING; CYTODIAGNOSIS; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PROGNOSIS; URINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84868238701     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21193     Document Type: Article

References (23)

1. Pu RT, Laitala LE, Clark DP. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006;50:499-506.
2. Friederich MG, Toma MI, Chun JK, et al. DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder [in German]. Urologe A. 2007;46:761-768.
3. Friederich MG, Blind C, Milde-Langosch K, et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol. 2001;40:518-524.
4. Quentin T, Henke C, Korabiowska M, Schlott T, Zimmerman B, Kunze E. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associate with tumor progression. Anticancer Res. 2004;24:1011-1023.
5. Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL. P16(INK4A) expression in urinary bladder carcinoma. Arch Ital Urol Androl. 2006;78:97-100.
6. Vallmanya LLena FR, Laborda Rodriguez A, Lloreta Trull J, Cortadellas Angel R, Placer Santos J, Mas Gelabert A. Immunohistochemical expression of p53, p21, p16 and cyclin D1 in superficial bladder cancer [in Spanish]. Acta Urol Esp. 2006;30:754-762.
7. Kruger S, Mahnken A, Kausch I, Feller AC. P16 Immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol. 2005;47:463-467.
8. Luo B, Li W, Deng CA, et al. Utility of FISH in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet. 2009;189:93-97.
9. LiHX, Li M, Li CL, et al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol. 2010;32:45-52.
10. Bardales R. Primary tumours of the urothelial tract. In: Practical Urologic Cytopathology. Oxford, UK: Oxford University Press; 2002:122-156.
11. Koss LG, Melamed MR. Tumors of the Urinary Tract in Urine and Brushings. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006:778-801.
12. Sokolova I, Halling K, Jenkins R, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123.
13. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008;15:279-286.
14. Halling K, King W, Sokolova I, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
15. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol. 2002;42:547-552.
16. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007; 127:295-301.
17. Eble JN, Sauter G, Epstein JI, Sesterheen IA. Tumors of the urinary system and male genital organs. In: WHO Classification of Tumors. Pathology and Genetics. Lyon, France: IARC Press; 2004:95.
18. Brimo F, Vollmer R, Case B, Aprikian A, Kassouf W, Auger M. Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol. 2009;132:785-793.
19. Bolenz C, West AM, Ortiz N, Kabbani W, Lotan Y. Urinary cytology for the detection of urothelial carcinoma of the bladder - a flawed adjunct to cystoscopy? Urol Oncol. [published online ahead of print March 15, 2011.]
20. Turco P, Houssami N, Bulgaresi P, et al. Is conventional urinary cytology still reliable for diagnosis of primary bladder carcinoma? Accuracy based on data linkage of a consecutive clinical series and cancer registry. Acta Cytol. 2011;55:193-196.
21. Nakazawa K, Murata S, Yuminamochi T, et al. P16INK4a expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol. 2009;132:776-784.
22. Ohtani N, Hara E. Regulation and function of p16INK4a tumor suppressor gene. Exp Med. 2003;21:713-720.
23. Okamura H, Kotoh S, Kamizaki H. Non-invasive detection of alterations in chromosome number in urinary bladder cancer cells using FISH. Int J Clin Oncol. 204;9:373-377.